Blog
RSS FeedPosted by Michael Wonder on 06 Feb 2023
Medical technology strategy
3 February 2023 - This document presents the inaugural UK medtech strategy and the timing could not be better. ...
Posted by Michael Wonder on 06 Feb 2023
TLV proposes a new process for health economic assessments that are made in a short time and under special circumstances
1 February 2023 - In a report to the government, the Dental and Pharmaceutical Benefits Agency, TLV, presents experiences and lessons ...
Posted by Michael Wonder on 04 Feb 2023
NICE’s new methods reflect society’s values
4 February 2023 - The mission of NICE is to get the best care to patients fast, while ensuring value for ...
Posted by Michael Wonder on 02 Feb 2023
Enhertu launched as gastric cancer tertiary treatment in Korea, insurance benefits loading
2 February 2023 - In an environment where gastric cancer treatments are currently lacking, the approval of Enhertu (ingredient: trastuzumab ...
Posted by Michael Wonder on 02 Feb 2023
Advanced breast cancer: now a significant added benefit for trastuzumab deruxtecan
2 February 2023 - New results from an early-initiated study show advantages in overall survival. ...
Posted by Michael Wonder on 01 Feb 2023
Nintedanib esylate for the treatment of adults with idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
1 February 2023 - Nintedanib esylate is recommended as an option for the treatment of adults with idiopathic pulmonary fibrosis ...
Posted by Michael Wonder on 01 Feb 2023
Somatrogon for treating growth disturbance in people 3 years and over
1 February 2023 - Somatrogon is recommended as an option for the treatment of children 3 years of age and over ...
Posted by Michael Wonder on 01 Feb 2023
Trastuzumab deruxtecan for treating HER2 positive unresectable or metastatic breast cancer after one or more anti-HER2 treatments
1 February 2023 - Trastuzumab deruxtecan is recommended with managed access as an option for the treatment of adults with HER2 ...
Posted by Michael Wonder on 01 Feb 2023
Upadacitinib monohydrate for the treatment of patients with active non-radiographic axial spondyloarthritis
1 February 2023 - Upadacitinib monohydrate is recommended as an option for the treatment of adults with active non-radiographic axial ...
Posted by Michael Wonder on 31 Jan 2023
Jazz Pharmaceuticals receives NICE recommendation for the reimbursement of Epidyolex (cannabidiol) for the treatment of seizures associated with tuberous sclerosis complex in England
31 January 2023 - Jazz Pharmaceuticals today announced that Epidyolex (cannabidiol 100 mg/mL oral solution), developed by GW Pharmaceuticals, has been ...
Posted by Michael Wonder on 27 Jan 2023
Highlights from the CHMP 23-26 January 2023 meeting
27 January 2023 - Four new medicines recommended for approval. ...
Posted by Michael Wonder on 27 Jan 2023
Dupixent (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis
27 January 2023 - Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent ...
Posted by Michael Wonder on 27 Jan 2023
Recommendations made by the PBAC – December 2022 intracycle meeting
27 January 2023 - Recommendations made by the PBAC in December 2022 relating to the listing of drugs on the PBS ...
Posted by Michael Wonder on 27 Jan 2023
Risankizumab for the treatment of patients with previously treated moderate to severe active Crohn's disease
27 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using risankizumab in ...
Posted by Michael Wonder on 27 Jan 2023
MSAC publishes agenda for April 2023 PASC meeting
27 January 2023 - The MSAC Secretariat has published a list of applications scheduled to be considered by the PICO Advisory ...